Literature DB >> 12660816

Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells.

Sandrine Lacour1, Olivier Micheau, Arlette Hammann, Véronique Drouineaud, Jurg Tschopp, Eric Solary, Marie-Thérèse Dimanche-Boitrel.   

Abstract

Cytokines such as Fas-ligand (Fas-L) and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) can induce human colon cancer cell apoptosis through engagement of their death domain receptors. All the cancer cells are not sensitive to these cytokines. We have shown recently that low doses of cytotoxic drugs could restore TRAIL-induced cell death in resistant colon cancer cell lines. The present work further explores the death pathway triggered by the cytotoxic drug/TRAIL combination in HT-29 colon cancer cells (www.alexis-corp.com). Clinically relevant concentrations of cisplatin, doxorubicin and 5-fluorouracil synergize with TRAIL to trigger HT-29 cell death. Activation of this pathway leads to apoptosis that involves both caspases and the mitochondria. An increased recruitment of Fas-associated death domain (FADD) and procaspase-8 to the TRAIL-induced death-inducing signaling complex (DISC) was shown in cells exposed to anticancer drugs. Following caspase-8 activation at the DISC level, the mitochondria-dependent death pathway is activated, as demonstrated by the cleavage of Bid, the dissipation of DeltaPsi(m), the release of mitochondrial proteins in the cytosol and the inhibitory effect of Bcl-2 expression. Importantly, besides mitochondrial potentiation, we show here that cytotoxic drugs sensitize HT-29 colon cancer cells to TRAIL-induced cell death by enhancing FADD and procaspase-8 recruitment to the DISC, a novel mechanism whose efficacy could depend partly on Bcl-2 expression level.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12660816     DOI: 10.1038/sj.onc.1206127

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  31 in total

1.  Association of active caspase 8 with the mitochondrial membrane during apoptosis: potential roles in cleaving BAP31 and caspase 3 and mediating mitochondrion-endoplasmic reticulum cross talk in etoposide-induced cell death.

Authors:  Dhyan Chandra; Grace Choy; Xiaodi Deng; Bobby Bhatia; Peter Daniel; Dean G Tang
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

2.  Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level.

Authors:  A Morizot; D Mérino; N Lalaoui; G Jacquemin; V Granci; E Iessi; D Lanneau; F Bouyer; E Solary; B Chauffert; P Saas; C Garrido; O Micheau
Journal:  Cell Death Differ       Date:  2010-11-12       Impact factor: 15.828

3.  The role of TRADD in TRAIL-induced apoptosis and signaling.

Authors:  Xiumei Cao; Yelena L Pobezinskaya; Michael J Morgan; Zheng-gang Liu
Journal:  FASEB J       Date:  2010-12-27       Impact factor: 5.191

4.  A cell-based high-throughput screen to identify synergistic TRAIL sensitizers.

Authors:  Nancy Lynn Booth; Thomas J Sayers; Alan D Brooks; Cheryl L Thomas; Kristen Jacobsen; Ekaterina I Goncharova; James B McMahon; Curtis J Henrich
Journal:  Cancer Immunol Immunother       Date:  2008-12-17       Impact factor: 6.968

5.  Valproic acid, an antiepileptic drug with histone deacetylase inhibitory activity, potentiates the cytotoxic effect of Apo2L/TRAIL on cultured thoracic cancer cells through mitochondria-dependent caspase activation.

Authors:  M Firdos Ziauddin; Wen-Shuz Yeow; Justin B Maxhimer; Aris Baras; Alex Chua; Rishindra M Reddy; Wilson Tsai; George W Cole; David S Schrump; Dao M Nguyen
Journal:  Neoplasia       Date:  2006-06       Impact factor: 5.715

6.  5-Fluorouracil preferentially sensitizes mutant KRAS non-small cell lung carcinoma cells to TRAIL-induced apoptosis.

Authors:  Haizhen Wang; Tao Yang; Xiangwei Wu
Journal:  Mol Oncol       Date:  2015-06-20       Impact factor: 6.603

7.  Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11.

Authors:  Patsy G Oliver; Albert F LoBuglio; Kurt R Zinn; Hyunki Kim; Li Nan; Tong Zhou; Wenquan Wang; Donald J Buchsbaum
Journal:  Clin Cancer Res       Date:  2008-04-01       Impact factor: 12.531

Review 8.  Cellular FLICE-inhibitory protein: an attractive therapeutic target?

Authors:  Olivier Micheau
Journal:  Expert Opin Ther Targets       Date:  2003-08       Impact factor: 6.902

9.  Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5.

Authors:  John B Fiveash; G Yancey Gillespie; Patsy G Oliver; Tong Zhou; Michael L Belenky; Donald J Buchsbaum
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-06-01       Impact factor: 7.038

10.  Anti-liver cancer activity of TNF-related apoptosis-inducing ligand gene and its bystander effects.

Authors:  Chao He; Wei-Feng Lao; Xiao-Tong Hu; Xiang-Ming Xu; Jing Xu; Bing-Liang Fang
Journal:  World J Gastroenterol       Date:  2004-03-01       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.